iShares MSCI Indonesia ETF vs Nuwellis Inc — how do they compare? iShares MSCI Indonesia ETF trades at $12.2, while Nuwellis Inc trades at $3.03 (market cap $1.10M). The key difference: iShares MSCI Indonesia ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| EIDO | NUWE | |
|---|---|---|
52-Week High | $19.22 | $558.26 |
52-Week Low | $10.80 | $2.80 |
Market Cap | — | $1.10M |
Sector | — | Technology |
Enterprise Value | — | -$709.83K |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Nuwellis (NUWE) trades at $3.22, up 15% in the last 24 hours, following a recent 35:1 reverse stock split executed on June 26, 2026. The medical technology company shows a mixed financial picture with a strong gross margin of 65.47% but significant net losses and negative profitability ratios. Recent news highlights expansion in pediatric care, new patent awards, and a $6 million public offering closed in June 2026 to fund operations. Technical indicators are predominantly bearish, with moving averages signaling strong selling pressure.
The outlook remains challenging due to persistent operating losses and negative cash flow, offset by strategic pediatric market expansion and new product innovation. Investment opportunity hinges on the company's ability to translate its high gross margin and recent capital raise into sustainable revenue growth and eventual profitability. Key risks include continued cash burn, execution of commercial strategy, and reliance on financing activities to fund operations.
Trailing returns across standard periods
Latest headlines on both assets
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →